||EPS - Basic
||Market Cap (m)
Animalcare Share Discussion Threads
Showing 76 to 94 of 100 messages
|Not a subscriber, but price moving up on the back of Buy suggestion in IC this week 'Buy Animalcare ahead of sales growth'|
|Results today and probably too boring for most. But I have taken a position.
Look at that upward trend, a story of consistent growth, rising dividends, strong cash generation and no debt.
Panmure still see it as a buy and have raised their target to 370p from 337p.
Looks to have some defensive qualities as well.
|Hitting a new high, if I'm not mistaken.
Last year we had a trading update on 9 July, maybe we are due one on Monday? Possible that some good news has leaked out in advance?|
|Heading towards resistance at 253p, although it's starting to look expensive on a forward P/E of 20. Maybe some news due about their product development projects?|
|True spread for 5000 shares has suddenly gone 206/207. A delayed trade to come ??|
|Did anyone attend the AGM today?|
|pre-close out this morning. Makes interesting reading:
The Board is pleased to report a solid trading performance for the year ended 30th June 2015. Revenues across the Group were up by 5.1% to £13.54m (2014: £12.88m) and underlying operating profits are at least in line with market expectations.
Revenue from sales of the Licensed Veterinary Medicines group was up 8.8% to £8.58m (2014: £7.88m) which includes encouraging sales of recently launched new products.
The Companion Animal Identification group revenues fell by 4.5% to £2.31m (2014: £2.42m), largely due to phasing of export equine chip sales where a substantial annual order was placed very late in the prior year. Whilst UK sales volumes were slightly up, net revenues were held back as a result of a national charity’s free microchipping campaign. Sales from the database services continued to rise in the year.
Sales from the Animal Welfare Products group rose by 2.6% to £2.65m (2014: £2.58m) with further improvement in gross profitability following the rationalisation of lower margin products in the prior year.
Overall underlying operating profit for the full year are at least £3.0m. The year-end cash position was £5.78m (30th June 2014: £3.81m). Continuing from the half year position, operating cash flows have been strong driven in particular by managed reduction in stock levels. Planned investment in our product pipeline in the year increased significantly on the prior year. Investment in the product development pipeline over the last two years is bearing fruit; three projects have reached important milestones in the second half and were submitted for regulatory approval.
Summary and Outlook
During the full year Animalcare launched five new products in the UK & Ireland, all on distribution. Pet Remedy was launched in the first half with sales above management expectations. Synthadon and Anaestamine were launched mid-way through the second half; both complement our increasing anaesthetics and analgesic ranges and are already selling strongly. Towards the end of the half Clavubactin and Fungiconazole were launched; the former is an antibacterial and the latter an antifungal medicine.
There is little evidence that dog owners are responding to the imminent compulsory chipping of dogs in England, Wales and Scotland (April 2016). However Animalcare has plans to grow microchip sales in the run up to this legislation and importantly the longer term.
The product development pipeline is progressing well with a further significant rise in capital expenditure forecast for the new financial year building on the increase in this reporting period.
Following the solid trading performance in the year, particularly from the Licensed Veterinary Medicines group, the Board remains confident about the prospects for the new financial year and is encouraged by the gaining momentum in the product development pipeline.|
|I'm hoping that someone knows something ...|
|Definitely going somewhere!|
|Surely just a minor bump on the road to nowhere!|
|What goes up.................!|
|Good question. Not seen or heard any bid speculation.
Could just be some over cautious PIs buying after the election. This is the sort of stock that cautious holders might like ...|
|So what is going on here then? I bought some at 178p on the recent dip and over the last week folk have been paying over the asking price to get 4k-5k's worth of stock, any reason for the demand?|
|Now above the Nov 13 peak. Wonder what the TA indicators have to say about that ;-)|
|sold out my small holding today after the rise, all the TA indicators now showing overbought and it's up against historic resistance. In a strong trending market similar to the last few years i would have continued to hold but we're in a a very volatile market just now so taking profits when you can and cutting losses early is more important.
Just about every company i review that's had decent results has seen the share price move up (some have remained static) only to retrace again within a few months and the number of profit warnings seems to be increasing too.
Markets for traders now imv.
|My comments on LSE about the annual report cover most of my thoughts on this
"Small revenue growth, inventory up by £1m+ or >30%. Cost of the board up again ~20%?. New Sales manager though 82% of revenue goes to 3 customers. Yet another Business Development Director, (every 2 years?) with the need for the department to grow.
I love the way the office move was made into a positive thing rather than just the lease ran out.
I guess we have to hope the Business Director gets someone to buy the company as the last two didn't"
And RD costs. Basically the company is top heavy for its size and they have four ways out it
1) Organic growth, hence R&D and Sales, actions in place just slow
2) Sell the business to a larger company, advertising material in place
3) Buy a company to absorb the overhead (they have been looking for a long time and this is probably the Chairman's favorite solution)
4) Reduce the Board overheads (hard to see turkeys voting for Christmas)|
|Why are profits forecast to drop this year? Is it increased R&D costs?|
|The company's chairman is very good at keeping the city informed. The annual report is always incredibly detailed and, to me, looks almost like a "for sale" brochure. That is not because the board especially want to sell the business but because, once public, the business is forever up for sale.
Having been on the inside, many years ago now, I understand the style of control within the company and it is very much "what you see on the can" hence they will develop new products on time etc.
The basic business makes it very non-cyclical while the pet chipping business is a fantastic cash cow that just keeps on giving
The two things that could change the share price are
1) a supplier failing to supply (has happened in recent years) and getting another supplier up and going takes a long time
2) someone buying it (Dechra should have snapped it up years ago)|
|SCROLL DOWN FOR LIST OF TRADES HERE